The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture

Taehoon Chun, Hyun Jung Byun, Yong Chung Hee, Yong Hoon Chung

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Lymphocyte activation gene-3 (LAG-3; CD223) is structurally similar to CD4 and binds to MHC class II with a 100-fold higher affinity than that of CD4. Soluble LAG-3 (sLAG-3Ig) might be useful for immunotherapy by inducing MHC class II-mediated cell activation. A new form of sLAG-3Ig was constructed containing a critical binding site (D1 and D2 region) to MHC class II, combined with a Fc portion of an immunoglobulin γ1. After treatment of sLAG-3Ig in fetal thymic organ culture from DO11.10 transgenic mouse, CD4+ T cell precursors were increased in the positive selection but not affected in the negative selection. Further analysis by treating sLAG-3Ig on thymic epithelial cells revealed that CD40 and MHC class II were up-regulated. These results may demonstrate that the treatment of sLAG-3Ig increases the precursor frequency of CD4+ T cells by activation of thymic epithelial cells.

Original languageEnglish
Pages (from-to)1371-1377
Number of pages7
JournalBiotechnology letters
Issue number17
Publication statusPublished - 2004 Sept
Externally publishedYes

Bibliographical note

Funding Information:
The authors thank Hae-Ja Lee for technical assistance. This work was supported by Korea Research Foundation Grant (KRF-2002-003-E00057).


  • Co-receptor
  • Fetal thymic organ culture
  • Fusion protein
  • Lymphocyte activation gene-3
  • T cell precursor
  • Thymic selection

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology


Dive into the research topics of 'The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture'. Together they form a unique fingerprint.

Cite this